Universal Beteiligungs und Servicegesellschaft mbH Makes New $38.65 Million Investment in Cencora, Inc. (NYSE:COR)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 172,032 shares of the company's stock, valued at approximately $38,652,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.09% of Cencora at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of COR. JFS Wealth Advisors LLC lifted its holdings in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares during the period. Banque Transatlantique SA acquired a new stake in Cencora in the fourth quarter valued at $29,000. SBI Securities Co. Ltd. acquired a new stake in Cencora in the fourth quarter valued at $30,000. Kentucky Trust Co acquired a new stake in Cencora in the fourth quarter valued at $33,000. Finally, WASHINGTON TRUST Co lifted its holdings in Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Price Performance

COR stock traded up $0.80 during trading on Friday, hitting $291.49. The stock had a trading volume of 3,890,003 shares, compared to its average volume of 1,537,835. The company's 50 day moving average price is $284.83 and its two-hundred day moving average price is $258.71. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The stock has a market cap of $56.50 billion, a price-to-earnings ratio of 41.46, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter in the previous year, the company posted $3.80 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.75%. The ex-dividend date is Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 4,970 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. The trade was a 8.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the sale, the chairman now owns 317,913 shares of the company's stock, valued at $85,680,732.63. The trade was a 4.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,223 shares of company stock worth $12,369,767 in the last 90 days. 10.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Bank of America lifted their price target on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Robert W. Baird lifted their price target on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Wells Fargo & Company lifted their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Finally, UBS Group lifted their price target on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $301.18.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.